COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - US19247A1007 - Common Stock
75.37 USD
-0.91 (-1.19%)
75.37 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to CNS. CNS was compared to 238 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
In the past year CNS has reported a negative cash flow from operations.
Each year in the past 5 years CNS has been profitable.
In the past 5 years CNS always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 21.59%, CNS belongs to the best of the industry, outperforming 98.74% of the companies in the same industry.
With an excellent Return On Equity value of 30.67%, CNS belongs to the best of the industry, outperforming 95.38% of the companies in the same industry.
With an excellent Return On Invested Capital value of 25.18%, CNS belongs to the best of the industry, outperforming 98.74% of the companies in the same industry.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROIC | 25.18% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
CNS's Profit Margin of 29.82% is fine compared to the rest of the industry. CNS outperforms 74.37% of its industry peers.
CNS's Profit Margin has declined in the last couple of years.
CNS's Operating Margin of 33.62% is in line compared to the rest of the industry. CNS outperforms 59.66% of its industry peers.
In the last couple of years the Operating Margin of CNS has declined.
CNS has a Gross Margin of 88.71%. This is amongst the best in the industry. CNS outperforms 92.44% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 11.76 indicates that CNS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.76, CNS belongs to the best of the industry, outperforming 94.54% of the companies in the same industry.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.76 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.87 indicates that CNS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.87, CNS is doing worse than 61.76% of the companies in the same industry.
CNS has a Quick Ratio of 0.87. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a worse Quick ratio (0.87) than 61.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
CNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.18%, which is quite good.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.54%.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)10.18%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.35%
Revenue 1Y (TTM)11.54%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%11.83%
3.2 Future
The Earnings Per Share is expected to grow by 5.88% on average over the next years.
The Revenue is expected to grow by 7.73% on average over the next years.
EPS Next Y5.31%
EPS Next 2Y8.26%
EPS Next 3Y10.74%
EPS Next 5Y5.88%
Revenue Next Year6.51%
Revenue Next 2Y7.33%
Revenue Next 3Y7.61%
Revenue Next 5Y7.73%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CNS is valuated rather expensively with a Price/Earnings ratio of 24.87.
62.18% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (27.14), we can say CNS is valued inline with the index average.
With a Price/Forward Earnings ratio of 21.95, CNS is valued on the expensive side.
The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
CNS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 21.95 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 75.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.69
PEG (5Y)9.96
EPS Next 2Y8.26%
EPS Next 3Y10.74%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.45%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 8.00, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.34, CNS pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.45% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
76.12% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.12%
EPS Next 2Y8.26%
EPS Next 3Y10.74%
75.37
-0.91 (-1.19%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners59.98%
Inst Owner Change0.33%
Ins Owners22.52%
Ins Owner Change-0.25%
Market Cap3.84B
Analysts48
Price Target80.24 (6.46%)
Short Float %7.02%
Short Ratio8.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.45% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.12%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.28%
Min EPS beat(2)-4.27%
Max EPS beat(2)-2.29%
EPS beat(4)0
Avg EPS beat(4)-2.29%
Min EPS beat(4)-4.27%
Max EPS beat(4)-0.35%
EPS beat(8)2
Avg EPS beat(8)-1.05%
EPS beat(12)5
Avg EPS beat(12)0.61%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.26%
PT rev (3m)-6.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.48%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.94%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)1.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 21.95 | ||
| P/S | 7.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.27 | ||
| P/tB | 7.56 | ||
| EV/EBITDA | 19.56 |
EPS(TTM)3.03
EY4.02%
EPS(NY)3.43
Fwd EY4.56%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS10.66
BVpS10.36
TBVpS9.97
PEG (NY)4.69
PEG (5Y)9.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROCE | 32.81% | ||
| ROIC | 25.18% | ||
| ROICexc | 30.38% | ||
| ROICexgc | 34.72% | ||
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexcg growth 3Y-36.94%
ROICexcg growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 55.86% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 11.76 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)10.18%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.35%
EPS Next Y5.31%
EPS Next 2Y8.26%
EPS Next 3Y10.74%
EPS Next 5Y5.88%
Revenue 1Y (TTM)11.54%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%11.83%
Revenue Next Year6.51%
Revenue Next 2Y7.33%
Revenue Next 3Y7.61%
Revenue Next 5Y7.73%
EBIT growth 1Y16.09%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year20.88%
EBIT Next 3Y17.3%
EBIT Next 5Y15.17%
FCF growth 1Y-196.88%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-177.85%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%